TCC1727 / Sino Biopharm - LARVOL DELTA

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=266 | Recruiting | Sponsor: Beijing Tide Pharmaceutical Co., Ltd

New P1/2 trial • Platinum resistant • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Myelodysplastic Syndrome • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • Thyroid Gland Carcinoma • ALK • BRAF • EGFR • KRAS • MSI • NRAS • PD-L1 • ROS1

A Phase I/II Clinical Study in Patients with Advanced Solid Tumor. (clinicaltrials.gov) - P1/2 | N=56 | Recruiting | Sponsor: Beijing Tide Pharmaceutical Co., Ltd | N=40 ➔ 56 | Trial completion date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Mar 2025 ➔ Jul 2025

Enrollment change • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Phase I/II Clinical Study in Patients With Advanced Solid Tumor. (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Beijing Tide Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Phase I/II Clinical Study in Patients With Advanced Solid Tumor. (clinicaltrials.gov) - P1/2 | N=40 | Not yet recruiting | Sponsor: Beijing Tide Pharmaceutical Co., Ltd

Metastases • New P1/2 trial • Oncology • Solid Tumor